From: Accelerated hyperfractionation plus temozolomide in glioblastoma
Overall Collective | NFRT | AHFRT | p-value | |||||
---|---|---|---|---|---|---|---|---|
(n = 131) | (n = 67) | (n = 64) | ||||||
Median Age (min/max) [y] | 61 | 12/80 | 63 | 43/78 | 59 | 12/80 | p < 0.001 (*) | |
Mean PTV ± sd [ccm] | 355 | ±142 | 339 | ±141.4 | 373 | ±141.8 | p = 0.17 | |
n | % | n | % | n | % | |||
Gender | m | 88 | 67.2 % | 46 | 68.7 % | 42 | 65.6 % | p = 0.85 |
f | 43 | 32.8 % | 21 | 31.3 % | 22 | 34.4 % | ||
Localization | Frontal | 42 | 32.1 % | 16 | 23.9 % | 26 | 40.6 % | p = 0.38 |
Parietal | 31 | 23.7 % | 17 | 25.4 % | 14 | 21.9 % | ||
Temporal | 38 | 29.0 % | 22 | 32.8 % | 16 | 25.0 % | ||
Occipital | 9 | 6.9 % | 4 | 6.0 % | 5 | 7.8 % | ||
Central | 9 | 6.9 % | 6 | 9.0 % | 3 | 4.7 % | ||
n/a | 2 | 1.5 % | 2 | 3.0 % | 0 | 0.0 % | ||
MGMT-status | unmethylated | 63 | 48.1 % | 32 | 47.8 % | 31 | 48.4 % | p = 0.66 |
methylated | 43 | 32.8 % | 23 | 34.3 % | 20 | 31.3 % | ||
n/a | 25 | 19.1 % | 12 | 17.9 % | 13 | 20.3 % | ||
Extent of surgery | Biopsy | 16 | 12.2 % | 6 | 9.0 % | 10 | 15.6 % | p = 0.38 |
Partial resection | 57 | 43.5 % | 28 | 41.8 % | 29 | 45.3 % | ||
Gross tumor resection | 51 | 38.9 % | 29 | 43.3 % | 22 | 34.4 % | ||
n/a | 7 | 5.3 % | 4 | 6.0 % | 3 | 4.7 % | ||
KPS | 50 % | 7 | 5.3 % | 4 | 6 % | 3 | 4.7 % | p = 0.3 |
60 % | 49 | 37.4 % | 27 | 40 % | 22 | 34.4 % | ||
70 % | 47 | 35.9 % | 24 | 36 % | 23 | 35.9 % | ||
80 % | 28 | 21.4 % | 12 | 18 % | 16 | 25.0 % | ||
Temozolomide | yes | 126 | 96.2 % | 65 | 97.0 % | 61 | 95.3 % | p = 0.68 |
no | 5 | 3.8 % | 2 | 3.0 % | 3 | 4.7 % | ||
Salvage treatment | Re-irradiation | 20 | 15.3 % | 12 | 17.9 % | 8 | 12.5 % | |
Chemotherapy (tmz) | 45 | 34.4 % | 24 | 35.8 % | 21 | 32.8 % | ||
Chemotherapy (other) | 6 | 4.6 % | 3 | 4.5 % | 3 | 4.7 % | ||
Bevacizumab | 11 | 8.4 % | 5 | 7.5 % | 6 | 9.4 % | ||
Imatinib | 1 | 0.8 % | 0 | 0.0 % | 1 | 1.6 % | ||
Dendritic cell vaccination | 1 | 0.8 % | 1 | 1.5 % | 0 | 0.0 % |